This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance
by Zacks Equity Research
The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.
Here's Why Investors Should Buy Edwards Lifesciences Now
by Zacks Equity Research
Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
McKesson Banks on Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson (MCK) entered fiscal 2018 with an assumption of branded inflation in the mid-single digits. Pricing pressure in the independent retail pharmacy channel is a headwind.
BioTelemetry Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
BioTelemetry (BEAT) is putting efforts in product innovation through research and development. The company recently announced the acquisition of LifeWatch AG in a deal valued at about $280 million.
Invacare (IVC) Introduces TDX SP2 Power Wheelchair Globally
by Zacks Equity Research
Invacare Corporation's (IVC) newly launched TDX SP2 Power Wheelchair would greatly help in capturing the highly competitive global wheelchair market.
PRA Health Sciences (PRAH) Prices Secondary Stock Offering
by Zacks Equity Research
PRA Health Sciences' (PRAH) move to procure funds through secondary offering is likely to enhance its bottom line and shareholders' returns.
Varian Medical (VAR) Signs Distribution Deal with Bionix
by Zacks Equity Research
Varian Medical's (VAR) new distribution agreement with Bionix Radiation Therapy would strengthen its radiotherapy business in North America.
Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine
by Zacks Equity Research
Solid share price rally following the news suggests that the latest development is likely to buoy Meridian's (VIVO) bottom line and enhance its illumigene platform.
Fresenius Medical Inks $2B Deal to Take Over NxStage Medical
by Zacks Equity Research
Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
IDEXX Laboratories (IDXX) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
IDEXX Laboratories' (IDXX) growth across all its segments in Q2 is encouraging.
Medical Products Earnings Due on Aug 1: IDXX, RMD
by Zacks Equity Research
There are some powerful long-term tailwinds of the medical device industry which have been a major driving force behind the sector's impressive performance over the past few quarters.
Why Earnings Season Could Be Great for IDEXX Laboratories (IDXX)
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
MedTech Stocks to Top Q2 Estimates
by Zacks Equity Research
Most of the MedTech majors are lined up to report their earnings results over the next week.
What's in the Offing for Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.
IDEXX Laboratories (IDXX) Q2 Earnings: A Beat in the Cards?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
DENTSPLY SIRONA Renews Canadian Distribution Agreement
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY), a dental solutions company, recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc.
Luminex Gets CE Mark for ARIES Norovirus Assay, Shares Rally
by Zacks Equity Research
Shares of Luminex Corporation (LMNX) gained 1.5% to close at $21.38 after the company announced the receipt of CE-IVD mark for the ARIES Norovirus Assay.
IDEXX Well-Poised on Strong Fundamentals, Global Growth
by Zacks Equity Research
On 29, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
CryoLife Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Leading medical device and tissue processing company, CryoLife, Inc. (CRY) rallied to a new 52-week high of $20.20 on Jun 27, eventually closing a little lower at $19.65.
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that it has entered into a multi-year partnership with inVentiv Health, a leading biopharmaceutical professional services company.
Merit Medical Embosphere Gets FDA de novo Classification
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) recently announced the receipt of 513(f)(2) (de novo) classification for Embosphere Microspheres from the FDA to expand its indication in the prostatic artery embolization (PAE) space.
Evolent Health (EVH) Prices 4.5M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 4.5 million shares of Class A common stock at $25.90 per share.
PRA Health Hits a 52-Week High on Strategic Acquisitions
by Zacks Equity Research
Leading global contract research organization PRA Health Sciences (PRAH) rallied to a new 52-week high of $78.30 on Jun 21, closing a little lower at $77.21.